Skip to main content
Novartis
language-selector-globe
Choose Location
  • International
  • Americas
  • Asia Pacific
  • Europe
  • Middle East & Africa
Global | English
Novartis Foundation | English
Argentina | Español
Brazil | Português
Canada | English
Canada | Français
Central America | Español
Colombia | Español
Mexico | Español
United States | English
Australia | English
Bangladesh | English
Hong Kong S.A.R. | 繁體中文
India | English
Indonesia | English
Japan | 日本語
Korea | 한국어
Mainland China | 中文
Malaysia | English
Pakistan | English
Philippines | English
Singapore | English
Taiwan | 繁體中文
Thailand | ภาษาไทย
Austria | Deutsch
Belgium | Français
Belgium | Nederlands
Bulgaria | Български
Czech Republic | Česky
Czech Republic | English
Denmark | Dansk
Estonia | Eesti
Finland | Suomalainen
France | Français
Germany | Deutsch
Greece | Ελληνικά
Hungary | Magyar
Ireland | English
Italy | Italiano
Latvia | Latvian
Lithuania | Lithuanian
Netherlands | Nederlands
Norway | Norsk
Poland | Polski
Portugal | Português
Romania | Română
Russia | Русский
Serbia | Srpski
Slovakia | Slovensky
Slovenia | Slovenščina
Slovenia | English
Spain | Español
Sweden | Svenska
Switzerland | Deutsch
Switzerland | Français
Türkiye | Türkçe
United Kingdom | English
Egypt | English
Israel | עברית
Saudi Arabia | العربية
South Africa | English
language-selector-globe
Choose Location
International Americas Asia Pacific Europe Middle East & Africa
Argentina | Español
Australia | English
Austria | Deutsch
Bangladesh | English
Belgium | Français
Belgium | Nederlands
Brazil | Português
Bulgaria | Български
Canada | English
Canada | Français
Central America | Español
Colombia | Español
Czech Republic | Česky
Czech Republic | English
Denmark | Dansk
Egypt | English
Estonia | Eesti
Finland | Suomalainen
France | Français
Germany | Deutsch
Greece | Ελληνικά
Hong Kong S.A.R. | 繁體中文
Hungary | Magyar
India | English
Indonesia | English
Ireland | English
Israel | עברית
Italy | Italiano
Japan | 日本語
Korea | 한국어
Latvia | Latvian
Lithuania | Lithuanian
Mainland China | 中文
Malaysia | English
Mexico | Español
Netherlands | Nederlands
Norway | Norsk
Global | English
Novartis Foundation | English
Pakistan | English
Philippines | English
Poland | Polski
Portugal | Português
Romania | Română
Russia | Русский
Saudi Arabia | العربية
Serbia | Srpski
Singapore | English
Slovakia | Slovensky
Slovenia | Slovenščina
Slovenia | English
South Africa | English
Spain | Español
Sweden | Svenska
Switzerland | Deutsch
Switzerland | Français
Taiwan | 繁體中文
Thailand | ภาษาไทย
Türkiye | Türkçe
United Kingdom | English
United States | English
    • About 
      • Board of Directors 
        • Giovanni Caforio 
        • Simon Moroney 
        • Ton Buechner 
        • Patrice Bula 
        • Elizabeth (Liz) Doherty 
        • Ana de Pro Gonzalo 
        • Bridgette Heller 
        • Daniel Hochstrasser 
        • Frans van Houten 
        • Elizabeth McNally 
        • John D. Young 
        • Charlotte Pamer-Wieser 
      • Executive Committee 
        • Vasant (Vas) Narasimhan 
        • Shreeram Aradhye 
        • Victor Bulto 
        • Aharon (Ronny) Gal 
        • Karen L. Hale 
        • Patrick Horber 
        • Harry Kirsch 
        • Rob Kowalski 
        • Steffen Lang 
        • Fiona Marshall 
        • Lutz Hegemann 
        • Kees Roks 
        • Michelle Weese 
      • Products 
      • Therapeutic areas 
        • Cardiovascular, renal and metabolic 
        • Immunology 
        • Neuroscience 
        • Oncology 
      • People and culture 
      • Inclusion 
        • Promoting inclusion 
        • Building belonging 
        • Parental leave 
      • Novartis Gene Therapies 
      • Manufacturing 
      • Quality 
        • Audit program 
        • Novartis quality management system (QMS) 
        • Product and patient safety training 
        • Regulatory inspections 
        • Product recalls 
        • Third-party suppliers 
      • Awards and recognition 
      Mother and daughter cuddling on a bed in a kids room

      About

      Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide.

    • Patients and caregivers 
      • Novartis commitment to patients and caregivers 
      • Diseases 
      • Patient organization funding 
      • Patients perspectives stories 
      Adult daughter talking to her senior parents on a bench in a park

      Patients and caregivers

      Information for patients and their caregivers including clinical trial recruiting, managed access programs, funding opportunities for patient organizations and side effects reporting.

    • Healthcare professionals 
      • Medical congresses and events 
        • ASCO Annual Meeting 
      • Products 
      • Novartis pipeline 
      • Managed access programs 
        • Zolgensma® Global Managed Access Program (gMAP) 
      • Novartis external funding 
      • Healthcare professional resources by country 
      • Investigator-initiated trials / studies 
      • Novartis medical information 
        • Submit medical enquiry 
      Doctor discussing illness with patient in an office

      Healthcare professionals

      Resources for physicians and other healthcare professionals including clinical trial recruiting, grant funding, congresses and country-level information.

    • Research and development 
      • Technology platforms 
      • Research disease areas 
        • Cardiovascular and metabolic disease research at Novartis 
        • DAx: exploratory disease research at Novartis 
        • Global Health disease area research at Novartis 
        • Immunology disease research at Novartis 
        • Neuroscience research at Novartis 
        • Oncology research at Novartis 
      • Novartis pipeline 
      • Research collaborations 
      • Collaborations 
      A female research scientist in a lab looking at a sample

      Research & development

      Discover how Novartis turns breakthrough science into transformative, high-value treatments.
       

    • ESG 
      • Access 
        • Creating sustainable business models 
        • Value-based pricing 
        • Sub-Saharan Africa 
        • Donations 
        • Novartis access principles 
        • Novartis oncology access 
        • Patents and licensing 
      • Environmental sustainability 
        • Climate 
        • Nature - Waste 
        • Nature - Water 
      • Ethics, risk and compliance 
        • Ethical behavior 
        • Compliance 
        • Human rights 
        • Learning and engagement 
        • Integrated risk assurance 
      • Global health 
        • Pandemic preparedness 
        • Avoidable blindness 
        • Chagas disease 
        • Leprosy 
        • Malaria 
        • Sickle cell disease (SCD) 
        • Novartis Foundation 
      • Inclusion 
      • ESG index 
      • Reporting and transparency hub 
        • ESG rating performance 
        • Targets 
        • Patient organization funding 
        • Payments to healthcare professionals 
        • Public policy 
        • A living wage 
        • A safe workplace 
        • Animal research 
      Family and friends having a party at home

      Environmental, social and governance

      Learn about our commitments to making a positive impact on the world by providing access to innovative medicines, protecting the environment, and upholding high ethical standards. Explore the Novartis in Society Integrated Report.

    • Investors 
      • Event calendar 
      • Financial data 
        • Novartis annual results 
        • Novartis quarterly results 
        • Novartis SEC filings 
        • Product sales 
        • Fixed-income securities 
        • Expected currency impact 
      • Share data and analysis 
        • Share monitor 
        • Dividend information 
        • Share ownership 
        • Share overview 
        • Return on investment calculator 
      • Shareholder information 
        • General Meetings 
        • American Depositary Receipts (ADR) 
        • Share buyback 
        • Frequently asked questions 
      • Company overview 
        • Corporate governance 
      • Reporting and transparency hub 
        • Reporting archive 
        • ESG rating performance 
        • Publications order form 
      • ESG 
      Business woman working on her laptop in a bright atmosphere

      Investors

      Updates and resources for investors including financial information, disclosures, events, share price, ESG and reporting.

    • News 
      • News archive  
      • Media library  
      • Stories 
      • Subscribe 
      • Events 
      Overhead view of a meeting room with people in the foreground and screens in the background

      News

      Information for journalists including media releases, statements, stories, multimedia resources and more.

    • Careers 
      • Career search 
      • Our business functions 
        • Careers in research and development 
        • Careers in operations 
        • Careers in commercial and sales 
        • Careers in global functions 
      • Why Novartis 
      • Career hub 
        • Temporary contracts 
      • Early careers 
        • Graduates 
        • Students 
        • US Biomedical Research internship programs 
        • Community exploration and learning lab (CELL) 
      Two business people

      Careers

      Novartis is hiring! Find open positions, learn more about our strategy and culture, and apply today.

    • Clinical trials 
    • Partnering 
    • Supplier portal 
    • Report side effects 
    • Contacts 
    Grandmother, mother and daughter smiling and laughing on a beach

    Home

    Working together, we can reimagine medicine to improve and extend people’s lives.

Stories

Story Navigation
  • All Topics
  • Discovery
  • From Our Labs
  • Patient Perspectives
  • Access to Healthcare
  • People & Culture
icon
  • Stopping Alzheimer's disease before it starts
    Discovery
    Biomedical ResearchDiseasesMedical InnovationsClinical Trials
    Jul 19, 2021

    Stopping Alzheimer's disease before it starts

    Novartis collaborates with the Banner Alzheimer’s Institute to test treatments for preventing Alzheimer’s disease.

    Discovery
  • MS misconceptions
    Patient Perspectives
    Access to HealthcareChronic IllnessDiseasesLiving With Disease
    Aug 6, 2021

    Debunking the myths about multiple sclerosis

    We surveyed 7,000 people in seven countries to find out what they know about multiple sclerosis (MS). Our survey identified several surprising misconceptions.

    Patient Perspectives
  • Novartis cancer researchers advance precision medicine
    Discovery
    Novartis Institutes for BioMedical ResearchReimagine MedicineNext Generation SequencingTargeted TherapyClinical TrialsCancer Research Institute
    Jul 16, 2021

    Novartis cancer researchers advance precision medicine

    Learn how NIBR uses next generation sequencing to transform clinical trials and diagnostics in oncology.

    Discovery
  • Heart failure patient receives care from his doctor
    Patient Perspectives
    Chronic IllnessHeart FailureLiving With Disease
    Aug 9, 2021

    Heart failure: coping with one of the world’s biggest killers

    Patients are learning to live with a chronic disease that will affect one in 5 people over age 40.

    Patient Perspectives
  • Stopping free radicals at their source
    From Our Labs
    Biomedical ResearchNovartis Institutes for BioMedical ResearchNew Scientific DiscoveriesScientific ResearchBiomedical Science
    Jul 20, 2021

    Stopping free radicals at their source

    Compounds that block the production of damaging molecules might shed light on their role in disease—and lead to new therapies.

    From Our Labs
  • Dr Chang as Xinh, waits for patients at the community hospital in Mu Cang Chai, rural Vietnam.
    Access to Healthcare
    Access to HealthcareCancerChronic IllnessFuture of HealthcareNovartis AccessNovartis Social Business
    Jul 21, 2021

    Confronting the global spread of chronic disease

    Chronic diseases like cancer and diabetes were once the preserve of wealthy countries but are now increasingly common in lower-income countries too as populations age and lifestyles change.

    Access to Healthcare
  • Healthcare worker, Dismus Mwalukwanda, discussing with a group of people in a rural part of Zambia
    Access to Healthcare
    Access to HealthcareDisease EradicationInfectious DiseasesMalariaNovartis Social BusinessTropical Diseases
    Aug 4, 2021

    Malaria fighter rides bicycle into battle with disease

    Healthcare worker Dismus Mwalukwanda is on the front line of the battle against malaria. Saving lives is his priority.

    Access to Healthcare
  • Putting patients first
    Patient Perspectives
    Novartis Institutes for BioMedical ResearchClinical ResearchCareersClinical TrialsClinical Science
    Aug 9, 2021

    Putting patients first

    Chinweike Ukomadu thinks that notions about clinicians turning their backs on patients when transitioning to industry are outdated.

    Patient Perspectives
  • Turning research advances into innovative medicines
    Discovery
    Novartis Institutes for BioMedical ResearchMusculoskeletal DiseasesCareers
    Jul 19, 2021

    Turning research advances into innovative medicines

    A strong background in biological research prepared Daniel Rooks for his role in shaping the early clinical development of new medicines

    Discovery
  • Five things to look for in a scientific mentor
    From Our Labs
    Biomedical ResearchNovartis Institutes for BioMedical ResearchPostdoc ProgramScientific Research
    Jul 19, 2021

    Five things to look for in a scientific mentor

    From Our Labs
  • How I built a mini-gut with next to no biology training
    From Our Labs
    Biomedical ResearchNovartis Institutes for BioMedical ResearchScientific ResearchBiomedical Science
    Jul 19, 2021

    How I built a mini-gut with next to no biology training

    From Our Labs
  • Rewriting the playbook for clinical testing in a rare disease
    Discovery
    Novartis Institutes for BioMedical ResearchRare DiseasesClinical TrialsGenetic Disease
    Jul 19, 2021

    Rewriting the playbook for clinical testing in a rare disease

    A Novartis team blazes new trails with an experimental treatment for spinal muscular atrophy.

    Discovery

Pagination

  • ‹ Previous page
  • 1
  • …
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • …
  • 33
  • › Next page

Novartis

Working together
  • Patients and caregivers
  • Healthcare professionals
  • Researchers
  • Job seekers
  • Journalists
  • Investors
Topics
  • Eurovision
  • Access
  • ESG
  • SpeakUp
Explore
  • Pipeline
  • Products
  • Clinical trials
  • Partnering
  • Events
Therapeutic areas
  • Cardiovascular, renal and metabolic
  • Immunology
  • Neuroscience
  • Oncology
Footer Bottom
© 2025 Novartis AG
  • Terms of use
  • Privacy
  • Cookie settings
  • Contacts
  • Locations
  • Site map
  • Open source
  • Web accessibility
Novartis Site Directory
This site is intended for a global audience